Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Chachlaki K, Garthwaite J, Prevot V
Circulation 145(8):565574
It was first approved in 2022 by the FDA for the treatment of adults with type II diabetes mellitus (T2DM)
The Specialist Pharmacy Service (UK) advises switching to a GLP-1 receptor agonist rather than adding a DPP-4 inhibitor like Januvia when intensifying therapy
If you switch immediately without a washout, weight typically continues downward or holds steady
Long-term efficacy considerations favour both agents, though from different perspectives
US$ 28.61
US$ 28.70
US$ 23.21
US$ 25.17
US$ 29.60
US$ 20.41
US$ 20.70
US$ 25.58
